After successfully overcoming prolonged regulatory and importing challenges, the paediatric dispersible fixed-dose combinations of first-line anti-tuberculosis drugs are now available for Spanish children. This experience may be useful for other countries. https://bit.ly/3uQz0eO

The authors would like to express their gratitude to Lindsay McKenna (Treatment Action Group, New York, NY, USA), James Seddon (Imperial College, London, UK), Brenda Waning (Global Drug Facility, Geneva, Switzerland), Kenneth Castro (Emory University, Atlanta, GA, USA) and Esteve Salse (Macleods Pharmaceuticals Ltd, Barcelona, Spain) for their support in this initiative.

Conflict of interest: The authors have no potential conflicts of interest to disclose.

Support statement: This work was partially supported by a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), reference PI22/00766, and by the Spanish Society of Pneumology and Thoracic Surgery, grant number 169-2022. Funding information for this article has been deposited with the Crossref Funder Registry.